Home
Diseases
Pruritus

Pruritus

Disease

Related News

Bimekizumab Durable Improvements in Psoriasis Over 3 Years in BE RADIANT Trial

Jul 14, 2026

In the BE RADIANT phase 3b trial, bimekizumab provided greater and durable improvements in patient-reported symptoms, skin clearance, and quality of life over 3 years compared with secukinumab in moderate to severe plaque psoriasis. At week 4, significantly more patients on bimekizumab achieved complete absence of itching, skin pain, and scaling. The benefits were sustained through 3 years, including after patients switched from secukinumab.

European Commission expands Pfizer's Hympavzi approval for hemophilia patients with inhibitors

May 14, 2026

The European Commission expanded Hympavzi approval to patients 12 and older with hemophilia A or B with inhibitors. Phase 3 data showed a 93% reduction in mean treated annualized bleeding rate versus on-demand therapy.

FDA Accepts Two NDAs: Rusfertide for Polycythemia Vera, Tirabrutinib for CNS Lymphoma

Mar 02, 2026

The FDA has accepted New Drug Applications for rusfertide in polycythemia vera with Priority Review and tirabrutinib for relapsed/refractory primary CNS lymphoma under Accelerated Approval, with PDUFA dates set for Q3 2026 and December 2026 respectively.

Palvella Reports Positive Phase 3 Results for QTORIN Rapamycin in Rare Lymphatic Malformation

Feb 25, 2026

Palvella Therapeutics announced positive topline results from its Phase 3 SELVA study of QTORIN 3.9% rapamycin for microcystic lymphatic malformations, meeting all primary and secondary endpoints with strong tolerability. The company plans an NDA submission in H2 2026.

FDA Accepts Tirabrutinib Application for Relapsed Primary CNS Lymphoma

Feb 24, 2026

The FDA accepted a new drug application for tirabrutinib to treat relapsed or refractory primary central nervous system lymphoma, with a decision expected December 18, 2026. The application is supported by phase 2 trial data showing a 67% overall response rate.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07641530	Health Belief Model-Based Education for Pruritus and Quality of Life in Hemodialysis Patients	COMPLETED	NA
NCT07478133	Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in Humans	COMPLETED	NA
NCT07450716	Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus	NOT_YET_RECRUITING	EARLY_PHASE1
NCT07432386	Methotrexate Versus Apremilast for Pruritus in Psoriasis	NOT_YET_RECRUITING	PHASE4
NCT07317271	VR-PMR for Post-Burn Symptoms	RECRUITING	NA
NCT06931119	Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients	NOT_YET_RECRUITING	PHASE1
NCT06924840	A Clinical Study to Assess the Safety and Effectiveness of Utixira Lotion and Utixira Tablet in Healthy Adult Human Subjects With Dry or Sensitive Skin Prone to Mild to Moderate Pruritus and Urticaria	NOT_YET_RECRUITING	NA
NCT06800755	Evaluation of the Efficacy and Tolerance of the Medical Device RL3020-DP0364 in Adult Population With Stable Mild Plaque Psoriasis, Dry Skin and Pruritus	COMPLETED	NA
NCT06787794	Reducing Itch With Hypnosis and Virtual Reality	RECRUITING	NA
NCT06751056	Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch	RECRUITING	NA